Display options
Cite
Hummelink K, Muller M, Linders TC, et al. Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ Open Res. 2019;5(1)doi: 10.1183/23120541.00016-2019.
Hummelink, K., Muller, M., Linders, T. C., van der Noort, V., Nederlof, P. M., Baas, P., Burgers, S., Smit, E. F., Meijer, G. A., van den Heuvel, M. M., van den Broek, D., & Monkhorst, K. (2019). Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ open research, 5(1), . https://doi.org/10.1183/23120541.00016-2019
Hummelink, Karlijn, et al. "Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions." ERJ open research vol. 5,1 (2019). doi: https://doi.org/10.1183/23120541.00016-2019
Hummelink K, Muller M, Linders TC, van der Noort V, Nederlof PM, Baas P, Burgers S, Smit EF, Meijer GA, van den Heuvel MM, van den Broek D, Monkhorst K. Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ Open Res. 2019 Mar 25;5(1). doi: 10.1183/23120541.00016-2019. eCollection 2019 Feb. PMID: 30918895; PMCID: PMC6431750.
Copy Download .nbib Format: NLM
Share it on

ERJ Open Res. 2019 Mar 25;5(1). doi: 10.1183/23120541.00016-2019. eCollection 2019 Feb.

Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions.

ERJ open research

Karlijn Hummelink, Mirte Muller, Theodora C Linders, Vincent van der Noort, Petra M Nederlof, Paul Baas, Sjaak Burgers, Egbert F Smit, Gerrit A Meijer, Michel M van den Heuvel, Daan van den Broek, Kim Monkhorst

Affiliations

  1. Dept of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  2. Dept of Thoracic Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  3. Dept of Laboratory Medicine, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  4. Dept of Biometrics, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, The Netherlands.
  5. Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

PMID: 30918895 PMCID: PMC6431750 DOI: 10.1183/23120541.00016-2019

Abstract

OBJECTIVES: Molecular profiling of tumours has become the mainstay of diagnostics for metastasised solid malignancies and guides personalised treatment, especially in nonsmall cell lung cancer (NSCLC). In current practice, it is often challenging to obtain sufficient tumour material for reliable molecular analysis. Cell-free DNA (cfDNA) in blood or other bio-sources could present an alternative approach to obtain genetic information from the tumour. In a retrospective cohort we analysed the added value of cfDNA analysis in pleural effusions for molecular profiling.

METHODS: We retrospectively analysed both the supernatant and the cell pellet of 44 pleural effusions sampled from 39 stage IV patients with

RESULTS: The driver mutation could be detected in 36 of the 44 pleural effusions by analysis of both the supernatant (35 out of 44 positive) and the cell pellet (31 out of 44 positive). In seven out of 20 pleural effusions from patients with

CONCLUSIONS: cfDNA in pleural effusion can be used to detect driver mutations as well as resistance mechanisms like

Conflict of interest statement

Conflict of interest: K. Hummelink has nothing to disclose. Conflict of interest: M. Muller has nothing to disclose. Conflict of interest: T.C. Linders has nothing to disclose. Conflict of interest: V

References

  1. Clin Cancer Res. 2009 Mar 15;15(6):2076-84 - PubMed
  2. Respiration. 2012;83(5):367-76 - PubMed
  3. J Clin Oncol. 2013 Mar 10;31(8):1039-49 - PubMed
  4. PLoS One. 2014 Feb 28;9(2):e89946 - PubMed
  5. Cancer Discov. 2014 Sep;4(9):1046-61 - PubMed
  6. Int J Clin Exp Pathol. 2014 Dec 01;7(12):8813-22 - PubMed
  7. J Clin Oncol. 2016 Oct 1;34(28):3375-82 - PubMed
  8. Clin Chem Lab Med. 2017 Oct 26;55(12):1962-1969 - PubMed
  9. Cytopathology. 2018 Apr;29(2):150-155 - PubMed
  10. Int J Oncol. 2018 Jun;52(6):2110-2118 - PubMed
  11. BMC Cancer. 2018 Dec 10;18(1):1236 - PubMed

Publication Types